Allelic variations in CYP2B6 and CYP2C19 and survival of patients receiving cyclophosphamide prior to myeloablative hematopoietic stem cell transplantation

American Journal of Hematology

Volumn 85, Issue 12, 2010, Pages 967-971

  Melanson, Stacy E F ^a   Stevenson, Kristen ^b   Kim, Haesook ^b   Antin, Joseph H ^b   Court, Michael H ^c   Ho, Vincent T ^b   Ritz, Jerome ^b   Soiffer, Robert J ^b   Kuo, Frank C ^a   Longtine, Janina A ^a   Jarolim, Petr ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; CYTOCHROME P450 2B6; CYTOCHROME P450 2C19;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOCYTIC LEUKEMIA; ADULT; ALLELISM; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; CANCER MORTALITY; CANCER PATIENT; CANCER RELAPSE; CANCER SURVIVAL; CARDIOTOXICITY; DRUG MEGADOSE; DRUG METABOLISM; FEMALE; GENETIC VARIABILITY; GENOTYPE; HOMOZYGOSITY; HUMAN; IDIOPATHIC PNEUMONIA SYNDROME; LETTER; LIVER VEIN OBSTRUCTION; MAJOR CLINICAL STUDY; MALE; MYELOABLATIVE CONDITIONING; MYELODYSPLASTIC SYNDROME; MYELOPROLIFERATIVE DISORDER; OVERALL SURVIVAL; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL;

ALLELES; ARYL HYDROCARBON HYDROXYLASES; CYCLOPHOSPHAMIDE; FEMALE; GENETIC VARIATION; GENOTYPE; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; MIDDLE AGED; MYELOABLATIVE AGONISTS; OXIDOREDUCTASES, N-DEMETHYLATING; SURVIVAL ANALYSIS; TRANSPLANTATION CONDITIONING;

EID: 78649514878     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.21889     Document Type: Letter

References (30)

1. Chabner BA, Ryan DP, Paz-Ares L, et al. Antineoplastic agents. In: Hardman JC, Limbird LE, editors. Goodman and Gilman's The Pharmacologic Basis of Therapeutics. New York: McGraw-Hill; 2001. pp 1389-1459.
2. de Jonge ME, Huitema AD, Rodenhuis S, Beijnen JH. Clinical pharmacokinetics of cyclophosphamide. Clin Pharmacokinet 2005; 44: 1135-1164.
3. Weinshilboum R. Inheritance and drug response. N Engl J Med 2003; 348: 529-537.
4. Ekhart C, Rodenhuis S, Smits PH, et al. Relations between polymorphisms in drug-metabolising enzymes and toxicity of chemotherapy with cyclophosphamide, thiotepa and carboplatin. Pharmacogenet Genomics 2008; 18: 1009-1015.
5. Xie H, Griskevicius L, Stahle L, et al. Pharmacogenetics of cyclophosphamide in patients with hematological malignancies. Eur J Pharm Sci 2006; 27: 54-61.
6. Xie HJ, Yasar U, Lundgren S, et al. Role of polymorphic human CYP2B6 in cyclophosphamide bioactivation. Pharmacogenomics J 2003; 3: 53-61.
7. Ekhart C, Doodeman VD, Rodenhuis S, et al. Influence of polymorphisms of drug metabolizing enzymes (CYP2B6, CYP2C9, CYP2C19, CYP3A4, CYP3A5, GSTA1, GSTP1, ALDH1A1, and ALDH3A1) on the pharmacokinetics of cyclophosphamide and 4-hydroxycyclophosphamide. Pharmacogenet Genomics 2008; 18: 515-523.
8. Chang TK, Yu L, Goldstein JA, Waxman DJ. Identification of the polymorphically expressed CYP2C19 and the wild-type CYP2C9-ILE359 allele as low-Km catalysts of cyclophosphamide and ifosfamide activation. Pharmacogenetics 1997; 7: 211-221.
9. Griskevicius L, Yasar U, Sandberg M, et al. Bioactivation of cyclophosphamide: The role of polymorphic CYP2C enzymes. Eur J Clin Pharmacol 2003; 59: 103-109.
10. Goldstein JA. Clinical relevance of genetic polymorphisms in the human CYP2C subfamily. Br J Clin Pharmacol 2001; 52: 349-355.
11. Timm R, Kaiser R, Lotsch J, et al. Association of cyclophosphamide pharmacokinetics to polymorphic cytochrome P450 2C19. Pharmacogenomics J 2005; 5: 365-373.
12. Hiratsuka M, Takekuma Y, Endo N, et al. Allele and genotype frequencies of CYP2B6 and CYP3A5 in the Japanese population. Eur J Clin Pharmacol 2002; 58: 417-421.
13. Accessed 9/14/2010.
14. de Jonge ME, Huitema AD, Beijnen JH, Rodenhuis S. High exposures to bioactivated cyclophosphamide are related to the occurrence of veno-occlusive disease of the liver following high-dose chemotherapy. Br J Cancer 2006; 4: 1226-1230.
15. Zver S, Zadnik V, Bunc M, et al. Cardiac toxicity of high-dose cyclophosphamide in patients with multiple myeloma undergoing autologous hematopoietic stem cell transplantation. Int J Hematol 2007; 85: 408-414.
16. Rocha V, Porcher R, Fernandes JF, et al. Association of drug metabolism gene polymorphisms with toxicities, graft-versus-host disease and survival after HLA-identical sibling hematopoietic stem cell transplantation for patients with leukemia. Leukemia 2009; 23: 545-556.
17. McCune JS, Batchelder A, Deeg HJ, et al. Cyclophosphamide following targeted oral busulfan as conditioning for hematopoietic cell transplantation: Pharmacokinetics, liver toxicity, and mortality. Biol Blood Marrow Transplant 2007; 13: 853-862.
18. Tran A, Bournerias F, Le Beller C, et al. Serious haematological toxicity of cyclophosphamide in relation to CYP2B6, GSTA1, and GSTP1 polymorphisms. Br J Clin Pharmacol 2008; 65: 279-280.
19. Nakajima M, Komagata S, Fujiki Y, et al. Genetic polymorphisms of CYP2B6 affect the pharmacokinetics/pharmacodynamics of cyclophosphamide in Japanese cancer patients. Pharmacogenet Genomics 2007; 17: 431-445.
20. Bray J, Sludden J, Griffin MJ, et al. Influence of pharmacogenetics on response and toxicity in breast cancer patients treated with doxorubicin and cyclophosphamide. Br J Cancer 2010; 102: 1003-1009.
21. Hesse LM, He P, Krishnaswamy S, et al. Pharmacogenetic determinants of interindividual variability in bupropion hydroxylation by cytochrome P450 2B6 in human liver microsomes. Pharmacogenetics 2004; 14: 225-238.
22. Lang T, Klein K, Fischer J, et al. Extensive genetic polymorphism in the human CYP2B6 gene with impact on expression and function in human liver. Pharmacogenetics 2001; 11: 399-415.
23. van Schaik RH. Cancer treatment and pharmacogenetics of cytochrome P450 enzymes. Invest New Drugs 2005; 23: 513-522.
24. Elmaagacli AH, Koldehoff M, Steckel NK, et al. Cytochrome P450 2C19 loss-of-function polymorphism is associated with an increased treatment-related mortality in patients undergoing allogeneic transplantation. Bone Marrow Transplant 2007; 40: 659-664.
25. Zanger UM, Klein K, Saussele T, et al. Polymorphic CYP2B6: Molecular mechanisms and emerging clinical significance. Pharmacogenomics 2007; 8: 743-759.
26. Cutler C, Stevenson K, Kim HT, et al. Sirolimus is associated with veno-occlusive disease of the liver after myeloablative allogeneic stem cell transplantation. Blood 2008; 112: 4425-4431.
27. Roy P, Yu LJ, Crespi CL, Waxman DJ. Development of a substrate-activity based approach to identify the major human liver P-450 catalysts of cyclophosphamide and ifosfamide activation based on cDNA-expressed activities and liver microsomal P-450 profiles. Drug Metab Dispos 1999; 27: 655-666.
28. Eriksson S, Berg LM, Wadelius M, Alderborn A. Cytochrome p450 genotyping by multiplexed real-time DNA sequencing with pyrosequencing technology. Assay Drug Dev Technol 2002; 1: 49-59.
29. Gray RJ. A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 1988; 16: 1140-1154.
30. Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 1999; 94: 469-509.